4DMT shares are trading lower. The company announced the presentation of Phase 2 PRISM interim data.
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (FDMT) shares are trading lower following the announcement of interim data from their Phase 2 PRISM study.
July 17, 2024 | 7:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
4D Molecular Therapeutics (FDMT) shares are trading lower after the company announced interim data from its Phase 2 PRISM study.
The release of interim data from clinical trials can significantly impact biotech stocks. In this case, the market has reacted negatively to the Phase 2 PRISM interim data, causing FDMT shares to trade lower.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100